Introduction Differentiated thyroid cancer (DTC) is the most frequently occurring endocrine cancer and its incidence has been increasing steadily in men and women over the last few decades ( 1 , 2 , 3 ). DTC includes papillary thyroid cancer
Search Results
Eugenie S Lim, Shanty G Shah, Mona Waterhouse, Scott Akker, William Drake, Nick Plowman, Daniel M Berney, Polly Richards, Ashok Adams, Ewa Nowosinska, Carmel Brennan and Maralyn Druce
Erika Urbano Lima, Ileana G S Rubio, Joaquim Custodio Da Silva, Ana Luiza Galrão, Danielle Pêssoa, Taise Cerqueira Oliveira, Fabiane Carrijo, Igor Silva Campos, Luciano Fonseca Espinheira, Luiz Jose Sampaio, Claudio Rogerio Lima, Janete Maria Cerutti and Helton Estrela Ramos
Introduction Differentiated thyroid cancer (DTC) has continued to increase over the past several decades, likely due to enhanced detection ( 1 , 2 ). Cancer research, in general, has benefited greatly from many of the new scientific
Natalie Su-Jing Yap, Richard Maher and Diana Louise Learoyd
-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer . European Journal of Endocrinology 2007 157 101 – 107 . ( doi:10.1530/EJE-07-0088 ). 5 Boi F Baghino G Atzeni F Lai ML Faa G
Susana Pastor, Abdelmounaim Akdi, Eddy R González, Juan Castell, Josefina Biarnés, Ricard Marcos and Antonia Velázquez
SNPs genotyped in THRB or the two genotyped SNPs in TSHR . Table 3 Genotype frequencies of the selected SNPs and their association with differentiated thyroid cancer in a Spanish population. SNP Genotype Control, n (%) DTC, n (%) Odds ratio a
Andrea Mazurat, Andrea Torroni, Jane Hendrickson-Rebizant, Harbinder Benning, Richard W Nason and K Alok Pathak
-based historical cohort includes all 2125 consecutive well-differentiated thyroid cancers diagnosed in 2115 patients in the province of Manitoba, Canada, from January 1, 1970 to December 31, 2010. We reviewed the individual electronic and paper records of diagnosis
Tiemo S Gerber, Arno Schad, Nils Hartmann, Erik Springer, Ulrich Zechner and Thomas J Musholt
indicative of an early event in thyroid tumorigenesis ( 28 ). All this leads to the assumption that the presence of SMAD4 mutations cannot differentiate between well-differentiated thyroid cancer and PDTC. KIT encodes for a tyrosine kinase receptor and
Danuta Gąsior-Perczak, Iwona Pałyga, Monika Szymonek, Artur Kowalik, Agnieszka Walczyk, Janusz Kopczyński, Katarzyna Lizis-Kolus, Anna Słuszniak, Janusz Słuszniak, Tomasz Łopatyński, Ryszard Mężyk, Stanisław Góźdź and Aldona Kowalska
Introduction Increased access to imaging techniques and fine-needle aspiration cytology (FNAC) has resulted in an increase in the rate of detection of differentiated thyroid cancer (DTC) in recent years ( 1 , 2 , 3 , 4 ). The increase in
T P McVeigh, R J Mulligan, U M McVeigh, P W Owens, N Miller, M Bell, F Sebag, C Guerin, D S Quill, J B Weidhaas, M J Kerin and A J Lowery
remained ill-defined. A recent meta-analysis has revisited the possibility of such an association and has confirmed the existence of, and quantified the increased co-occurrence of breast and differentiated thyroid cancer (DTC) ( 1 ). Both cancers occur
M L Gild, M Bullock, C K Pon, B G Robinson and R J Clifton-Bligh
. Journal of Clinical Endocrinology and Metabolism 2006 91 2389 – 2395 . ( doi:10.1210/jc.2005-2480 ). 16 Gild ML Landa I Ryder M Ghossein RA Knauf JA Fagin JA . Targeting mTOR in RET mutant medullary and differentiated thyroid cancer
Norra Kwong, Ellen Marqusee, Michael S Gordon, P Reed Larsen, Jeffrey R Garber, Matthew I Kim and Erik K Alexander
Introduction Well-differentiated thyroid cancer is common, easily identified, and often curable. While the incidence of thyroid cancer has nearly tripled in the past three decades, mortality rates have remained stable (1, 2, 3) . This underscores
